This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia

This study is currently recruiting participants.
See Contacts and Locations
Verified August 2008 by Imperial College London
The Margaret Hayton HHT Fund
Information provided by (Responsible Party):
Imperial College London Identifier:
First received: September 29, 2005
Last updated: May 28, 2015
Last verified: August 2008
The Hammersmith Hospital provides a clinical service for patients with Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations that is unique in the United Kingdom. Measurements obtained as part of standard clinical practice that has evolved since 1985 allow us to assess whether particular groups of individuals that we see are more prone to recognised complications such as strokes, brain abscesses, pregnancy related complications or pulmonary hypertension. We hypothesise that certain clinical characteristics will predict the susceptibility of individuals to particular complications.

Telangiectasia, Hereditary Hemorrhagic

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Hammersmith Hospital Patients With Pulmonary Arteriovenous Malformations (PAVMs) and Hereditary Haemorrhagic Telangiectasia

Resource links provided by NLM:

Further study details as provided by Imperial College London:

Primary Outcome Measures:
  • Stroke [ Time Frame: Prospective ]
  • Venous thromboemboli (VTE) [ Time Frame: Prospective ]

Estimated Enrollment: 500
Study Start Date: January 2000
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients referred to the hereditary haemorrhagic telangiectasia clinical service at Hammersmith Hospital, imperial College Healthcare NHS Trust

Inclusion Criteria:

  • Patients attending Hammersmith Hospital

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00230685

Contact: Claire L Shovlin 0208 383 1000

United Kingdom
Respiratory Medicine, Hammersmith Hospital Recruiting
London, United Kingdom, W12 0NN
Contact: Claire L Shovlin   
Principal Investigator: Claire L Shovlin         
Sponsors and Collaborators
Imperial College London
The Margaret Hayton HHT Fund
Principal Investigator: Claire L Shovlin Imperial College London
  More Information


Responsible Party: Imperial College London Identifier: NCT00230685     History of Changes
Other Study ID Numbers: IC/CLS2
Study First Received: September 29, 2005
Last Updated: May 28, 2015

Keywords provided by Imperial College London:
Pulmonary arteriovenous malformations

Additional relevant MeSH terms:
Arteriovenous Malformations
Arteriovenous Fistula
Vascular Malformations
Cardiovascular Abnormalities
Congenital Abnormalities
Telangiectasia, Hereditary Hemorrhagic
Vascular Diseases
Cardiovascular Diseases
Hemostatic Disorders
Hemorrhagic Disorders
Hematologic Diseases
Vascular Fistula
Pathological Conditions, Anatomical processed this record on September 20, 2017